 SAN DIEGO, May 10, 2021 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO today reported financial results for the first quarter ended March 31, 2021 and provided an update on its recent corporate activities and outlook. The first quarter marked a strong start to 2021 highlighted by record quarterly royalty revenue driven by the continued successful launch of subcutaneous DARZALEX worldwide, said Dr. Helen Torley, president and chief executive officer. 